|
1
|
Lee SK, Ameno K, In SW, Yang JY, Kim KU,
Koo KS, Yoo YC, Ameno S and Ijiri I: Levels of paraquat in fatal
intoxications. Int J Legal Med. 112:198–200. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lin JL, Lin-Tan DT, Chen KH, Huang WH, Hsu
CW, Hsu HH and Yen TH: Improved survival in severe paraquat
poisoning with repeated pulse therapy of cyclophosphamide and
steroids. Intensive Care Med. 37:1006–1013. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang RL, Tang X, Wu X, Xu R, Yu KL and Xu
K: The relationship between HIF-1α expression and the early lung
fibrosis in rats with acute paraquat poisoning. Zhonghua Lao Dong
Wei Sheng Zhi Ye Bing Za Zhi. 30:273–277. 2012.(In Chinese).
PubMed/NCBI
|
|
4
|
Forman HJ, Aldrich TK, Posner MA and
Fisher AB: Differential paraquat uptake and redox kinetics of rat
granular pneumocytes and alveolar macrophages. J Pharmacol Exp
Ther. 221:428–433. 1982.PubMed/NCBI
|
|
5
|
Naito H and Yamashita M: Epidemiology of
paraquat in Japan and a new safe formulation of paraquat. Human
Toxicol. 6:87–88. 1987. View Article : Google Scholar
|
|
6
|
Rose MS, Smith LL and Wyatt I: Evidence
for energy-dependent accumulation of paraquat into rat lung.
Nature. 252:314–315. 1974. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
van der Wal NA, van Oirschot JF, van Dijk
A, Verhoef J and van Asbeck BS: Mechanism of protection of alveolar
type II cells against paraquat-induced cytotoxicity by
deferoxamine. Biochem Pharmacol. 39:1665–1671. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Venkatesan N: Pulmonary protective effects
of curcumin against paraquat toxicity. Life Sci. 66:PL21–P28.
2000.PubMed/NCBI
|
|
9
|
Tomita M, Okuyama T, Katsuyama H, Miura Y,
Nishimura Y, Hidaka K, Otsuki T and Ishikawa T: Mouse model of
paraquat- poisoned lungs and its gene expression profile.
Toxicology. 231:200–209. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hagiwara S, Iwasaka H, Matsumoto S and
Noguchi T: An antisense oligonucleotide to HSP47 inhibits
paraquat-induced pulmonary fibrosis in rats. Toxicology.
236:199–207. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wilson MS and Wynn TA: Pulmonary fibrosis:
Pathogenesis, etiology and regulation. Mucosal Immunol. 2:103–121.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Behr J: Evidence-based treatment
strategies in idiopathic pulmonary fibrosis. Eur Respir Rev.
22:163–168. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
King TE Jr, Pardo A and Selman M:
Idiopathic pulmonary fibrosis. Lancet. 378:1949–1961. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
American Thoracic Society. Idiopathic
pulmonary fibrosis, . Diagnosis and treatment. International
consensus statement. American Thoracic Society (ATS), and the
European Respiratory Society (ERS). Am J Respir Crit Care Med.
161:646–664. 2000.PubMed/NCBI
|
|
15
|
Kotani T, Makino S, Takeuchi T, Kagitani
M, Shoda T, Hata A, Tabushi Y and Hanafusa T: Early intervention
with corticosteroids and cyclosporin A and 2-hour postdose blood
concentration monitoring improves the prognosis of acute/subacute
interstitial pneumonia in dermatomyositis. J Rheumatol. 35:254–259.
2008.PubMed/NCBI
|
|
16
|
King TE Jr, Bradford WZ, Castro-Bernardini
S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM,
Kardatzke D, Lancaster L, et al: A phase 3 trial of pirfenidone in
patients with idiopathic pulmonary fibrosis. N Engl J Med.
370:2083–2092. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Richeldi L, du Bois RM, Raghu G, Azuma A,
Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y,
et al: Efficacy and safety of nintedanib in idiopathic pulmonary
fibrosis. New Eng J Med. 370:2071–2082. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Murphy MB, Moncivais K and Caplan AI:
Mesenchymal stem cells: Environmentally responsive therapeutics for
regenerative medicine. Exp Mol Med. 45:e542013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Baer PC: Adipose-derived mesenchymal
stromal/stem cells: An update on their phenotype in vivo and in
vitro. World J Stem Cells. 6:256–265. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Caruso M, Evangelista M and Parolini O:
Human term placental cells: Phenotype, properties and new avenues
in regenerative medicine. Int J Mol Cellular Med. 1:64–74.
2012.
|
|
21
|
Taha MF and Hedayati V: Isolation,
identification and multipotential differentiation of mouse adipose
tissue-derived stem cells. Tissue Cell. 42:211–216. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zuk PA, Zhu M, Mizuno H, Huang J, Futrell
JW, Katz AJ, Benhaim P, Lorenz HP and Hedrick MH: Multilineage
cells from human adipose tissue: Implications for cell-based
therapies. Tissue Eng. 7:211–228. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Weiss DJ: Stem cells, cell therapies, and
bioengineering in lung biology and diseases. Comprehensive review
of the recent literature 2010–2012. Ann Am Thorac Soc. 10:S45–S97.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Weiss DJ and Ortiz LA: Cell therapy trials
for lung diseases: Progress and cautions. Am J Respir Crit Care
Med. 188:123–125. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
McNulty K and Janes SM: Stem cells and
pulmonary fibrosis: Cause or cure? Proc Am Thorac Soc. 9:164–171.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ortiz LA, Gambelli F, McBride C, Gaupp D,
Baddoo M, Kaminski N and Phinney DG: Mesenchymal stem cell
engraftment in lung is enhanced in response to bleomycin exposure
and ameliorates its fibrotic effects. Proc Natl Acad Sci USA.
100:8407–8411. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Phan SH: The myofibroblast in pulmonary
fibrosis. Chest. 122 (Suppl 6):S286–S289. 2002. View Article : Google Scholar
|
|
28
|
Epperly MW, Guo H, Gretton JE and
Greenberger JS: Bone marrow origin of myofibroblasts in irradiation
pulmonary fibrosis. Am J Respir Cell Mol Biol. 29:213–224. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Scotton CJ and Chambers RC: Molecular
targets in pulmonary fibrosis: The myofibroblast in focus. Chest.
132:1311–1321. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Investigation.
119:1420–1428. 2009. View
Article : Google Scholar
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Husari A, Khayat A, Bitar H, Hashem Y,
Rizkallah A, Zaatari G and El Sabban M: Antioxidant activity of
pomegranate juice reduces acute lung injury secondary to hyperoxia
in an animal model. BMC Res Notes. 7:6642014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gong X, Sun Z, Cui D, Xu X, Zhu H, Wang L,
Qian W and Han X: Isolation and characterization of lung resident
mesenchymal stem cells capable of differentiating into alveolar
epithelial type II cells. Cell Biol Int. 38:405–411. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Strieter RM and Mehrad B: New mechanisms
of pulmonary fibrosis. Chest. 136:1364–1370. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Smith LL and Rose MS: A comparison of the
effects of paraquat and diquat on the water content of rat lung and
the incorporation of thymidine into lung DNA. Toxicology.
8:223–230. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vijeyaratnam GS and Corrin B: Experimental
paraquat poisoning: A histological and electron-optical study of
the changes in the lung. J Pathol. 103:123–129. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Maggini J, Mirkin G, Bognanni I, Holmberg
J, Piazzon IM, Nepomnaschy I, Costa H, Canones C, Raiden S,
Vermeulen M and Geffner JR: Mouse bone marrow-derived mesenchymal
stromal cells turn activated macrophages into a regulatory-like
profile. PLoS One. 5:e92522010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Anderson P, Souza-Moreira L, Morell M,
Caro M, O'Valle F, Gonzalez-Rey E and Delgado M: Adipose-derived
mesenchymal stromal cells induce immunomodulatory macrophages which
protect from experimental colitis and sepsis. Gut. 62:1131–1141.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kim C, Lee JM, Park SW, Kim KS, Lee MW,
Paik S, Jang AS, Kim DJ, Uh S, Kim Y and Park CS: Attenuation of
cigarette smoke-induced emphysema in mice by apolipoprotein A-1
overexpression. Am J Respir Cell Mol Biol. 54:91–102. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li Y, Li JS, Li WW, Li SY, Tian YG, Lu XF,
Jiang SL and Wang Y: Long-term effects of three Tiao-Bu Fei-Shen
therapies on NF-κB/TGF-β1/smad2 signaling in rats with chronic
obstructive pulmonary disease. BMC Complement Altern Med.
14:1402014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang C, Ding H, Tang X, Li Z and Gan L:
Effect of Liuweibuqi Capsules in pulmonary alveolar epithelial
cells and COPD through JAK/STAT pathway. Cell Physiol Biochem.
43:743–756. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Adamali HI and Maher TM: Current and novel
drug therapies for idiopathic pulmonary fibrosis. Drug Des Devel
Ther. 6:261–272. 2012.PubMed/NCBI
|
|
43
|
Whelan TP: Lung transplantation for
interstitial lung disease. Clinics Chest Med. 33:179–189. 2012.
View Article : Google Scholar
|
|
44
|
McShane PJ and Garrity ER Jr: Minimization
of immunosuppression after lung transplantation: Current trends.
Transpl Int. 22:90–95. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cargnoni A, Gibelli L, Tosini A, Signoroni
PB, Nassuato C, Arienti D, Lombardi G, Albertini A, Wengler GS and
Parolini O: Transplantation of allogeneic and xenogeneic
placenta-derived cells reduces bleomycin-induced lung fibrosis.
Cell Transplant. 18:405–422. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chang YS, Oh W, Choi SJ, Sung DK, Kim SY,
Choi EY, Kang S, Jin HJ, Yang YS and Park WS: Human umbilical cord
blood-derived mesenchymal stem cells attenuate hyperoxia-induced
lung injury in neonatal rats. Cell Transplant. 18:869–886. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Le Blanc K, Frassoni F, Ball L, Locatelli
F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger
M, et al: Mesenchymal stem cells for treatment of
steroid-resistant, severe, acute graft-versus-host disease: A phase
II study. Lancet. 371:1579–1586. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gao J, Dennis JE, Muzic RF, Lundberg M and
Caplan AI: The dynamic in vivo distribution of bone marrow-derived
mesenchymal stem cells after infusion. Cells Tissues, Organs.
169:12–20. 2001. View Article : Google Scholar
|
|
49
|
Rojas M, Xu J, Woods CR, Mora AL, Spears
W, Roman J and Brigham KL: Bone marrow-derived mesenchymal stem
cells in repair of the injured lung. Am J Respir Cell Mol Biol.
33:145–152. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Williams AR and Hare JM: Mesenchymal stem
cells: Biology, pathophysiology, translational findings, and
therapeutic implications for cardiac disease. Circ Res.
109:923–940. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Elnakish MT, Hassan F, Dakhlallah D, Marsh
CB, Alhaider IA and Khan M: Mesenchymal stem cells for cardiac
regeneration: Translation to bedside reality. Stem Cells Int.
2012:6460382012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Rathinasabapathy A, Bruce E, Espejo A,
Horowitz A, Sudhan DR, Nair A, Guzzo D, Francis J, Raizada MK,
Shenoy V and Katovich MJ: Therapeutic potential of adipose stem
cell-derived conditioned medium against pulmonary hypertension and
lung fibrosis. Br J Pharmacol. 173:2859–2879. 2016. View Article : Google Scholar : PubMed/NCBI
|
